Literature DB >> 15958550

Meningioma transcript profiles reveal deregulated Notch signaling pathway.

Ileana C Cuevas1, Alison L Slocum, Peter Jun, Joseph F Costello, Andrew W Bollen, Gregory J Riggins, Michael W McDermott, Anita Lal.   

Abstract

Meningiomas constitute the second most common central nervous system tumor, and yet relatively little is known about the molecular events that are important for the pathogenesis and malignant progression of these tumors. We have used serial analysis of gene expression to compare the transcriptomes of nonneoplastic meninges and meningiomas of all malignancy grades. A novel finding from this screen is the induction of three components of the Notch signaling pathway: the transcription factor, hairy and enhancer of Split1 (HES1) and two members of the Groucho/transducin-like enhancer of Split family of corepressors, TLE2 and TLE3. TLE corepressors interact and modulate the activity of a wide range of transcriptional regulatory systems, one of which is HES1. We have shown that the transcript and protein levels of HES1, the Notch2 and Notch1 receptors and the Jagged1 ligand are induced in meningiomas of all grades, whereas induction of TLE2 and TLE3 occurs specifically in higher-grade meningiomas. Meningioma cell lines express components of the Notch signaling pathway and an inhibitor of this pathway suppresses meningioma cell survival. These results suggest that deregulated expression of the Notch pathway is a critical event in meningioma pathogenesis and that modulation of this and potentially other signaling pathways by TLE corepressors leads to a more malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958550     DOI: 10.1158/0008-5472.CAN-05-0240

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Authors:  Lindsey M Hoffman; Maryam Fouladi; James Olson; Vinay M Daryani; Clinton F Stewart; Cynthia Wetmore; Mehmet Kocak; Arzu Onar-Thomas; Lars Wagner; Sridharan Gururangan; Roger J Packer; Susan M Blaney; Amar Gajjar; Larry E Kun; James M Boyett; Richard J Gilbertson
Journal:  Childs Nerv Syst       Date:  2015-05-01       Impact factor: 1.475

2.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

3.  Notch signaling enhances nestin expression in gliomas.

Authors:  Alan H Shih; Eric C Holland
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

4.  Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.

Authors:  V Fernández-Majada; C Aguilera; A Villanueva; F Vilardell; A Robert-Moreno; A Aytés; F X Real; G Capella; M W Mayo; L Espinosa; A Bigas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

5.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

6.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo.

Authors:  Peng Xu; Mingzhe Qiu; Zhiyong Zhang; Chunsheng Kang; Rongcai Jiang; Zhifan Jia; Guangxiu Wang; Hao Jiang; Peiyu Pu
Journal:  J Neurooncol       Date:  2009-09-22       Impact factor: 4.130

Review 8.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

9.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

10.  Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Authors:  Okay Saydam; Yiping Shen; Thomas Würdinger; Ozlem Senol; Elvan Boke; Marianne F James; Bakhos A Tannous; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Cornel Fraefel; James F Gusella; Anna M Krichevsky; Xandra O Breakefield
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.